09/01/2003
ReGen Therapeutics Plc (‘ReGen’ or the ‘Company’), a company whose product Colostrinin™ has recently shown efficacy as a potential treatment for Alzheimer’s disease, announces that a patent on the use of Colostrinin™ as an oxidative stress regulator has been granted by the United States Patent & Trademark Office. The patent is owned by the University of Texas Medical Branch, Galveston, Texas, USA (‘UTMB’), but is licensed to ReGen, via the long term research and license agreements that exist between the two parties.
The new patent covers the use of Colostrinin™ as an oxidative stress regulator for modulating the oxidative stress level in a cell. Evidence accumulated recently implicates oxidative stress in the pathogenesis of severe neurodegenerative diseases, including Alzheimer’s disease.
The grant of this patent adds further strength to the intellectual property portfolio owned by or licensed to ReGen. Three patents, relating to the use of Colostrinin™ to treat Alzheimer’s disease and other similar disease conditions, have already been granted and another, relating to its use in combination with other substances as a dietary supplement, was granted in October 2002. The Company has filed a number of other patent applications in relation to Colostrinin™ and these are currently being evaluated by the relevant patent authorities.
Commenting on the latest patent grant, Chairman Percy Lomax said ‘This is an extremely pleasing start to 2003, not only for ReGen, but also for our collaborative partners at UTMB. Our relationship with the University goes back several years and it is particularly pleasing to see the scientists’ hard work rewarded in such a way. We congratulate Drs. Stanton, Boldogh and Hughes on this grant and thank them all for the contribution they have made and are continuing to make to the activities of ReGen.’
For further information, please contact:
Andrew Marshall, Tel: 020 7489 2033
Marshall Robinson Roe